Lv3
250 积分 2022-07-13 加入
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial
2天前
已完结
Abstract CT034: Results from phase 3 KEYLYNK-008: Pembrolizumab (pembro) with and without maintenance olaparib (ola) after first-line (1L) pembro plus chemotherapy (chemo) for metastatic squamous non-small-cell lung cancer (sqNSCLC)
2个月前
已关闭
Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Deficient Thoracic Tumor
3个月前
已完结
SMARCA4 deficiency and mutations are frequent in large cell lung carcinoma and are prognostically significant
3个月前
已完结
Antibody–drug conjugates in gastric cancer: from molecular landscape to clinical strategies
4个月前
已完结
Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: A Phase II Multicenter Study
5个月前
已完结
Targeting DNA Damage Response Deficiency in Thoracic Cancers
5个月前
已完结
Spatiotemporal Concurrent PARP Inhibitor Sensitization based on Radiation‐Responsive Nanovesicles for Lung Cancer Chemoradiotherapy
6个月前
已完结
PARP inhibitor plus radiotherapy reshapes an inflamed tumor microenvironment that sensitizes small cell lung cancer to the anti-PD-1 immunotherapy
6个月前
已完结
Niraparib plus Dostarlimab in Pleural Mesothelioma or Non–Small Cell Lung Cancer Harboring HRR Mutations: Interim Results of the UNITO-001 Phase II Prospective Trial
6个月前
已完结
皖公网安备34019202002308
